Live Breaking News & Updates on Novel Device

Stay updated with breaking news from Novel device. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lineage Cell Therapeutics : Prospectus disclosing information, facts, events

Filed Pursuant to Rule 424

Registration No. 333-277758

PROSPECTUS SUPPLEMENT

Up to $39,966,424. ....

State Of California , United States , Tel Aviv , Roche Ltd , Lineage Cell Therapeutics Inc , Securities Exchange , American Company , Tel Aviv Stock Exchange , Eterna Therapeutics Inc , Exchange Commission , Implications Of Beinga Smaller Reporting Company , Roche Group , California Institute For Regenerative Medicine , B Riley Securities Inc , Genentech Inc , Filed Pursuant , Securities Act , Can Find More , Certain Information , Lineage Cell Therapeutics , License Agreement , California Institute , Investigational New Drug , Oligodendrocyte Progenitor Cells , Spinal Cord Injury , Novel Device ,

Lineage Cell Therapeutics : Immediate Report -March 24, 2024 at 04:37 am EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
. ....

New York , United States , City Of New York , Georgea Samuel , Subsidiary Of The Company , Commission File Number , Lineage Cell Therapeutics Inc , Exchange Commission The , Governmental Authority , B Riley Securities Inc , Cantor Fitzgerald Co , Company The Prospectus , Exchange Commission , Warranties Of The Company , Placement Shares Of The Company , Company Or Lineage , Financial Industry Regulatory Authority Inc , Public Company Accounting Oversight Board United States , United States Drug Enforcement Administration , Securities Exchange , Termination Of Prior Offering Program , Consent Of Sheppard Mullin Richter Hampton , Opinion Of Sheppard Mullin Richter Hampton , Neither The Company , Sales Of The Company , Drug Administration ,

Lineage Cell Therapeutics : FORM S-3-Registration Statements -March 10, 2024 at 04:43 am EDT

As filed with the Securities and Exchange Commission on March 7, 2024

Registration No. 333-

UNITED STATES

SECURITIES. ....

United States , State Of California , Tel Aviv , Georgea Samuel , Brianm Culley , Exchange Commission , Roche Group , Roche Ltd , Lineage Cell Therapeutics Inc , Genentech Inc , Implications Of Beinga Smaller Reporting Company , Exchange Commission On , California Institute For Regenerative Medicine , Tel Aviv Stock Exchange , Eterna Therapeutics Inc , Securities Exchange , Cell Therapeutics , Securities Act , Exchange Act , Certain Information , Can Find More Information , Lineage Cell Therapeutics , License Agreement , California Institute , Investigational New Drug , Oligodendrocyte Progenitor Cells ,

Lineage Cell Therapeutics : Annual report which provides a comprehensive overview of the company for the past year -March 10, 2024 at 04:43 am EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

. ....

United States , Israel General , United Kingdom , California Institute For Regenerative Medicine , Drug Administration , Eterna Therapeutics Inc , Securities Exchange , Cell Cure Neurosciences Ltd , Exchange Commission , Roche Group , Cell Therapy Technology Platform , Roche Ltd , Lineage Cell Therapeutics Inc , Cancer Research United Kingdom , Genentech Inc , Association For Research , Christopher Dana Reeve Foundation , Hadassah University Hospital , Cell Therapeutics , Zip Code , Securities Exchange Act , Interactive Data File , Regulations T , Sarbanes Oxley Act , Exchange Act , Annual Report ,

Exploring Keratoprosthesis: A Comprehensive Guide

Explore keratoprosthesis, artificial corneas, surgical techniques, and patient outcomes in this comprehensive guide. ....

United States , Alphacor Keratoprosthesis , Fyodorov Zuev Keratoprosthesis , American Academy Of Ophthalmology , Typei Keratoprosthesis , Cor Keratoprosthesis , Zuev Keratoprosthesis , Knowthe Boston Typei Keratoprosthesis , Failed Corneal Transplants , Ocular Surface Diseases , Surface Evaluation , Visual Acuity , Corneal Conditions , Visual Aids , Ocular Comfort , Treatment Options , Term Solution , Improved Social , Professional Engagement , Boston Type , Novel Device , American Academy , Artificial Cornea , Surgical Procedure , Patient Outcomes , Vision Restoration ,